[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prognostic-stratification\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prognostic-stratification":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100494162","evaluation-of-optical-genome-mapping-in-phi-negative-myeloproliferative-neoplasia-in-the-detection-of-acquired-cytogenetic-abnormalities-100494162",false,"NCT05714592","Evaluation of Optical Genome Mapping in Phi Negative Myeloproliferative Neoplasia in the Detection of Acquired Cytogenetic Abnormalities","MYELOCARTOCH","Inclusion Criteria:\n\n* Patient 18 years of age or older\n* Diagnosis or follow-up of polycythemia vera, essential thrombocythemia or primary or secondary myelofibrosis\n* Requires bone marrow cytogenetics at diagnosis or follow-up\n* Understanding of the French language\n* Information of the patient and collection of no objection\n* Person affiliated to a social security regime\n\nExclusion Criteria:\n\n* Patient with BCR::ABL positive myeloproliferative neoplasia.\n* Person with a medical history that may impair the ability to understand the information notice","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","INTERVENTIONAL",[23],"NA","Standard cytogenetics (CBA +\u002F- FISH) is of diagnostic and prognostic interest in Ph- MPN. However, its value is limited by the low frequency of detected abnormalities. The development of tools to increase the sensitivity of detection of chromosomal alterations is therefore particularly adapted to these pathologies. Optical genome mapping (OGM) is a high resolution \"long read\" technique that allows the identification of structural and copy number variations at the whole genome level. Several recent studies suggest that OGM is a future tool for cytogenetic characterization of haematological disorders. Its ability to describe structural abnormalities, including balanced ones, represents a major advantage over currently used technologies. Thus, OGM seems to be the key tool for cytogenetics of haematological malignancies in the coming years, making it possible to replace, under certain conditions, not only karyotype and FISH, but CMA and even RT-MLPA for the search for fusion transcripts, thus filling in the gaps in these techniques while maintaining their advantages.\n\nTo define the place of this technology in Ph- MPN, the investigators will perform a OGM analysis on patients with Ph-MPN for whom bone marrow exploration is scheduled. These results will be compared with those of standard cytogenetics (CBA +\u002F- FISH).",[26,27,28,29,30],"Myeloproliferative Neoplasm","Optical Genome Mapping","Cytogenetics","Clonality","Prognostic Stratification",[26,32,28,29,33],"Optical genome mapping","Prognostic stratification","RECRUITING","2026-05-27",{"date":37,"type":38},"2026-05-28","ACTUAL",{"date":40,"type":38},"2023-05-17",{"date":42,"type":20},"2027-05-18",{"name":44,"class":45},"Centre Hospitalier Universitaire, Amiens","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":66,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":46},"100528865","interest-of-the-chair-lift-test-in-the-prognostic-evaluation-of-pulmonary-embolism-a-single-center-open-prospective-study-100528865","NCT06166329","Interest of the Chair Lift Test in the Prognostic Evaluation of Pulmonary Embolism: a Single-center Open Prospective Study","SIT-EP","Inclusion Criteria:\n\n* Diagnosis of pulmonary embolism according to clinical algorithm, confirmed by thoracic angioscan or ventilation perfusion (V\u002FP) scan,\n* Non-serious pulmonary embolism, not requiring intensive care (thrombectomy or fibrinolysis not considered).\n* sPESI score ≥ 1 \\[or = 0 with elevated troponin or presence of markers of VD dysfunction, or = 0 with need for hospitalization due to comorbidities unrelated to PE (social isolation, comprehension disorders, intercurrent infection, chronic renal failure, advanced cancer...)\n* Patients with no contraindications to chair lift testing (no O2 at the time of testing).\n* Effective anticoagulation for at least 1 hour.\n\nExclusion Criteria:\n\n* sPESI score = 0 with outpatient referral.\n* Diagnostic confirmation of Pulmonia Embolism by thoracic angioscan or scintigraphy more than 24h after suspicion of diagnosis.\n* Hospitalization \\> 24h after introduction of anticoagulation, with subsequent confirmation by scintigraphy.\n* Any sign of serious Pulmonia Embolism, requiring hospitalization in an intensive care unit.\n* Asymptomatic Pulmonia Embolism discovered by chance",{"count":55,"type":20},180,[23],"The objective of the study is to evaluate the prognostic performance of the chair lift test in the initial assessment of the severity of non-severe pulmonary embolism in hospitalized patients, in comparison with the current pulmonary embolism risk stratification score using the sPESI score refined by the use of cardiac biomarkers and right ventricular dysfunction",[59,60,61,62,30,63,64,65],"Non-severe Pulmonary Embolism","Pulmonary Embolism","Non-high-risk Pulmonary Embolism","Pulmonary Embolism Acute","Risk Assessment in Pulmonary Embolism","Functional Exercise Testing","Early Prognostic Evaluation",[60,67,68,69,70,71,72,73,74,75,76,77,78,79],"Prognostic Evaluation","Risk Stratification","sPESI Score","Chair Stand Test","One-Minute Sit-to-Stand Test","Functional Capacity","Right Ventricular Dysfunction","Cardiac Biomarkers","Troponin","NT-proBNP","Early Mortality","Ambulatory Management","Hospitalized Patients","2026-02-13",{"date":82,"type":38},"2026-02-17",{"date":84,"type":38},"2024-02-09",{"date":86,"type":20},"2027-02",{"name":88,"class":45},"University Hospital, Rouen"]